Monthly Archives: August 2013

FDA Advisory Committee recommends against approval of Tolvaptan for polycystic kidney disease

As noted in a previous posting, Tolvaptan, a vasopression type-2 receptor antagonist, currently approved for the treatment of clinically significant hypervolemic and euvolemic hyponatremia, is also being developed for the treatment of autosomal dominant polycystic kidney disease (ADPKD). ¬†Otsuka pharmaceuticals … Continue reading

Posted in M Loghman-Adham, MD | Leave a comment